• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

泛KRAS抑制剂BI-2493的发现及其疗效

Discovery of BI-2493, a Pan-KRAS Inhibitor Showing Efficacy.

作者信息

Bröker Joachim, Waterson Alex G, Hodges Timothy R, Abbott Jason R, Arnold Allison, Böttcher Jark, Braun Nina, Cui Jianwen, Fuchs Julian E, Gerstberger Thomas, Gogg Sebastian, Hanner Sabine, Herdeis Lorenz, Howell Lucas W, Mantoulidis Andreas, Mayer Moriz, Phan Jason, Rocchetti Francesca, Sankar Kyra, Sarkar Dhruba, Schaaf Otmar, Sensintaffar John L, Sun Qi, Wunberg Tobias, Fesik Stephen W

机构信息

Boehringer Ingelheim RCV GmbH & Co., KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria.

Vanderbilt University School of Medicine, Department of Biochemistry, 2215 Garland Ave., 607 Light Hall, Nashville, Tennessee 37232-0146, United States.

出版信息

J Med Chem. 2025 Aug 14;68(15):15649-15668. doi: 10.1021/acs.jmedchem.5c00576. Epub 2025 Jul 25.

DOI:10.1021/acs.jmedchem.5c00576
PMID:40709733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12362595/
Abstract

KRAS is one of the most highly validated cancer targets. Here we describe the design and synthesis of two reversible pan-KRAS inhibitors, BI-2865 and BI-2493. From our KRAS inhibitor program, we identified BI-2865, a potent noncovalent KRAS inhibitor that showed cellular activity against a broad spectrum of KRAS alleles and selectivity against HRAS and NRAS. Spirocyclization led to the discovery of BI-2493, a highly rigid analogue exhibiting better potency, metabolic stability, and permeability. BI-2493 shows efficacy in various KRAS mutant and KRAS wild-type amplified xenograft models and represents a promising starting point for further optimization.

摘要

KRAS是最经过充分验证的癌症靶点之一。在此，我们描述了两种可逆性泛KRAS抑制剂BI-2865和BI-2493的设计与合成。从我们的KRAS抑制剂项目中，我们鉴定出了BI-2865，一种强效非共价KRAS抑制剂，它对多种KRAS等位基因显示出细胞活性，并对HRAS和NRAS具有选择性。螺环化导致了BI-2493的发现，这是一种高度刚性的类似物，具有更好的效力、代谢稳定性和通透性。BI-2493在各种KRAS突变型和KRAS野生型扩增异种移植模型中均显示出疗效，是进一步优化的一个有前景的起点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/0c1b265df41d/jm5c00576_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/f2b5280d7edf/jm5c00576_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/f6fc40607650/jm5c00576_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/b539e10da487/jm5c00576_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/f55170f36325/jm5c00576_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/420a2fb32a82/jm5c00576_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/d2c7ff436b79/jm5c00576_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/4c79b2e0c2ed/jm5c00576_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/119d45b71975/jm5c00576_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/5f190c38d0fb/jm5c00576_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/a110c88884bf/jm5c00576_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/a989360c14ac/jm5c00576_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/86cb7c893a76/jm5c00576_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/b9012cdcb8a1/jm5c00576_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/0c1b265df41d/jm5c00576_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/f2b5280d7edf/jm5c00576_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/f6fc40607650/jm5c00576_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/b539e10da487/jm5c00576_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/f55170f36325/jm5c00576_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/420a2fb32a82/jm5c00576_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/d2c7ff436b79/jm5c00576_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/4c79b2e0c2ed/jm5c00576_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/119d45b71975/jm5c00576_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/5f190c38d0fb/jm5c00576_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/a110c88884bf/jm5c00576_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/a989360c14ac/jm5c00576_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/86cb7c893a76/jm5c00576_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/b9012cdcb8a1/jm5c00576_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea36/12362595/0c1b265df41d/jm5c00576_0014.jpg

相似文献

1
Discovery of BI-2493, a Pan-KRAS Inhibitor Showing Efficacy.泛KRAS抑制剂BI-2493的发现及其疗效
J Med Chem. 2025 Aug 14;68(15):15649-15668. doi: 10.1021/acs.jmedchem.5c00576. Epub 2025 Jul 25.
2
RAS mutation-specific signaling dynamics in response to paralog- and state- selective RAS inhibitors.响应旁系同源物和状态选择性RAS抑制剂的RAS突变特异性信号转导动力学
bioRxiv. 2025 Mar 21:2025.02.14.638317. doi: 10.1101/2025.02.14.638317.
3
Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.发现 ASP6918，一种 KRAS G12C 抑制剂：作为共价抑制剂的 1-{2,7-二氮杂螺[3.5]壬-2-基}丙-2-烯-1-酮衍生物的合成和构效关系，具有良好的效力和口服活性，用于治疗实体瘤。
Bioorg Med Chem. 2024 Jan 15;98:117581. doi: 10.1016/j.bmc.2023.117581. Epub 2023 Dec 27.
4
Specific inhibitor to KRAS induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy.KRAS特异性抑制剂可诱导肿瘤特异性免疫，并与溶瘤病毒协同作用以增强癌症免疫治疗效果。
J Immunother Cancer. 2025 Jul 23;13(7):e010514. doi: 10.1136/jitc-2024-010514.
5
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.基于替泊替尼和奥美拉唑联合用药的KRAS突变型非小细胞肺癌（NSCLC）治疗
Cell Commun Signal. 2024 Jun 12;22(1):324. doi: 10.1186/s12964-024-01667-x.
6
FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer.FGTI-2734抑制ERK再激活以克服KRAS G12C肺癌中的索托拉西布耐药性。
J Thorac Oncol. 2025 Mar;20(3):331-344. doi: 10.1016/j.jtho.2024.11.022. Epub 2024 Nov 26.
7
Adagrasib in the treatment of colorectal cancer.阿达格拉西布用于治疗结直肠癌。
Future Oncol. 2025 Jul 6:1-11. doi: 10.1080/14796694.2025.2524311.
8
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers.一种泛KRAS抑制剂及其衍生的降解剂在KRAS驱动的癌症中引发多方面的抗肿瘤功效。
Cancer Cell. 2025 Jul 25. doi: 10.1016/j.ccell.2025.07.006.
9
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.用于转移性结直肠癌的表皮生长因子受体（EGFR）抑制剂
Cochrane Database Syst Rev. 2017 Jun 27;6(6):CD007047. doi: 10.1002/14651858.CD007047.pub2.
10
ATR expression as a prognostic biomarker in -mutated non-small cell lung cancer.ATR表达作为KRAS突变型非小细胞肺癌的预后生物标志物。 （你提供的原文中“-mutated”这里应该是有个具体基因如“KRAS”等缺失了，我按照补充完整后的意思翻译了，如果不是这样请根据实际情况调整）
J Thorac Dis. 2025 Jul 31;17(7):5197-5209. doi: 10.21037/jtd-2025-1113. Epub 2025 Jul 29.

本文引用的文献

1
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers.达拉松拉西布（RMC-6236）的发现，一种强效且口服生物可利用的RAS（ON）多选择性、非共价三复合物抑制剂，用于治疗多种RAS成瘾性癌症患者。
J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8.
2
Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification.泛KRAS抑制剂BI-2493和BI-2865在具有KRAS野生型等位基因扩增的肿瘤中显示出强大的抗肿瘤活性。
Mol Cancer Ther. 2025 Apr 2;24(4):550-562. doi: 10.1158/1535-7163.MCT-24-0386.
3
Targeting cancer with small-molecule pan-KRAS degraders.
用小分子泛 KRAS 降解剂靶向癌症。
Science. 2024 Sep 20;385(6715):1338-1347. doi: 10.1126/science.adm8684. Epub 2024 Sep 19.
4
The current landscape of using direct inhibitors to target KRAS-mutated NSCLC.使用直接抑制剂靶向KRAS突变型非小细胞肺癌的现状。
Exp Hematol Oncol. 2023 Nov 4;12(1):93. doi: 10.1186/s40164-023-00453-8.
5
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.泛 KRAS 抑制剂使致癌信号和肿瘤生长失活。
Nature. 2023 Jul;619(7968):160-166. doi: 10.1038/s41586-023-06123-3. Epub 2023 May 31.
6
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS Inhibitor.片段优化使 KRAS 开关 II 口袋可逆结合，得到强效、体内有效的 KRAS 抑制剂。
J Med Chem. 2022 Nov 10;65(21):14614-14629. doi: 10.1021/acs.jmedchem.2c01120. Epub 2022 Oct 27.
7
Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation.JNJ-74699157 治疗携 KRAS G12C 突变的晚期实体瘤患者的 I 期研究。
Oncologist. 2022 Jul 5;27(7):536-e553. doi: 10.1093/oncolo/oyab080.
8
The path to the clinic: a comprehensive review on direct KRAS inhibitors.通往临床的道路：直接 KRAS 抑制剂的全面综述。
J Exp Clin Cancer Res. 2022 Jan 19;41(1):27. doi: 10.1186/s13046-021-02225-w.
9
KRAS mutation: from undruggable to druggable in cancer.KRAS 突变：从不可用药到癌症的可用药。
Signal Transduct Target Ther. 2021 Nov 15;6(1):386. doi: 10.1038/s41392-021-00780-4.
10
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.靶向 KRAS(G12C)：从抑制机制到调节患者的抗肿瘤作用。
Cell. 2020 Nov 12;183(4):850-859. doi: 10.1016/j.cell.2020.09.044. Epub 2020 Oct 15.